

Index

- 2-deoxy-D-glucose, 182
 6 Hz model, 54
- ABCB1 gene, 52, 53, 72
 abdominal aura, 89
 ablation volume, 213–215
 ablative surgery, 210–217
 background and clinical data, 211–213
 hardware and procedures, 210–211
 neurocognitive outcomes, 215
 specific complications, 217
 absence seizures
 atypical and typical, 137
 childhood, 174
 epilepsy with myoclonic absences, 131–135, 150
 juvenile, 144, 151
 models, 62
 accident risk, 46
 acetazolamide, 193
 acetoacetate, 241
 acetone, 241
 ACTH, 122, 127, 243
 acupuncture, 250
 adherence to medication, 60, 172
 AERRPS syndrome, 111
 aetiology and epilepsy syndromes, 6
 Affordable Health Care Act, 2010, 35
 alternative psychosis, 257, 260
 Alzheimer's disease, 144
 Americans with Disabilities Act (ADA), 35
 Ammon's horn, 87
 AMPAR antibodies, 101, 107
 amygdalohippocampal stimulation, 95
 animal models, 53–54, 62
 anterior nucleus of the thalamus stimulation, 225
 empiric, 54–56
 known mechanisms, 56–58
 overview, 55
 anisatin, 251
 ANNA-1 antibodies, 102, 108
 anterior frontopolar region, 162
 anterior nucleus of the thalamus (ANT), 224–225
 stimulation, 225–228
- anterior temporal lobectomy (ATL), 94
 anthroposophic medicine, 253
 antidepressants, 264, 265
 antiepileptic drugs (AEDs). *See* anti-seizure medications (ASMs)
 anti-inflammatory, 63
 antipsychotics, 264, 265
 anti-seizure medications (ASMs), 1–4, 69
 adverse effects, 23
 autoimmune epilepsy, 114
 defined daily doses, 22
 development of new, 75–76
 efficacy and tolerability of add-ons, 182
 first treatment failure, 6, 179–180
 first treatment failure, monotherapy/polytherapy following, 180–181
 first-line treatment, 179
 novel ASMs, 182–183
 patterns of response, 15
 pharmacodynamics, 69, 72, 265
 pharmacokinetics, 69, 70–71
 pregnancy and, 190–191
 psychiatric adverse effects, 262
 RCTs assessing, 181–182
 reproductive hormones and, 189
 seizure freedom and, 24
 seizure-free rates, 16
 selection and utilization, 173
 specific epilepsy diagnoses, 174
 specific seizure types and, 21
 tolerance of, 261
 anxiety, 93, 257
 Apasmara, 249
 arteriovenous malformations, 161
 atonic seizures, 136, 140
 auras, 89, 158
 autoantibodies, 74, 89, 100, 111, 115, 174
 autoimmune disorders, systemic, 109–110
 autoimmune encephalitis with seizures, 104–108
 autoimmune epilepsy, 100–115, 174
 clinical features, 100
 diagnosis, 100–105
 prognosis, 115
 treatment, 104, 112–115
 treatment, first-line therapy, 112–114
 treatment, second line therapy, 114
 automatism, 158
 Ayurveda, 248, 249, 251
- Behçet's disease, 110
 benign familial neonatal seizures, 120
 benign familial neonatal-infantile seizures, 120
 beta-hydroxybutyrate, 241
 biomarkers, 64–66, 74
 genetic, 74
 botanical treatments, 248–254
 developed countries, 250
 developing countries, 248, 250
 regulatory issues, 250–251
 safety issues, 251
 status of clinical use, 252–253
 unmet medical need for, 248
 brain responsive neurostimulation. *See* responsive neurostimulation
 brain tumors, 165
 breast feeding, 194
- cancer, 60, 9, 72
 autoimmune epilepsy and, 101
 cannabidiol, 75, 130, 131, 248, 251, 252, 253
 cannabis, 75, 248, 253
 carbamazepine, 2, 22, 53, 73, 114, 179
 cardiac arrhythmias, 44
 catamenial epilepsy, 187, 188, 192
 cavernous angiomas, 161
 cellular plasticity, 53
 cenobamate, 182
 cerebrovascular lesions, 166
 channelopathies, 53
 childbearing, 34, 179, 194
 childhood absence epilepsy, 174
 childhood syndromes, 136–149
 childhood-onset epilepsy, 118–151. *See also* SUDEP
 behavioural disorders, 256
 infant syndromes, 121–135
 ketogenic diet, 242, 243
 mortality risk, 7

Index

- childhood-onset epilepsy (cont.)
 neonatal syndromes, 118–121
 remission rates, 2–3
 surgery for, 148
 timing of diagnosis, 5
 transition of care in, 149
- cingulate gyrus, 162
- Clinical Pharmacogenetics
 Implementation Consortium
 (CPIC), 71
- clobazam, 71, 193, 234
- clozapine, 264
- CNS lupus, 110
- coeliac disease, 110
- cognitive impairment, 137, 176, 256
 psychiatric disorders and, 263
 resective surgery and, 206
- cognitive morbidity, 46
- complementary health approaches, 250
- congenital bilateral perisylvian
 polymicrogyria, 83, 84
- congenital cytomegalovirus, 79
- consensus definition, need for, 20–24
- corticosteroids, 104, 105, 112
- costs. *See* economics
- counselling, 176
- Crohn's disease, 110
- cryptogenic epilepsy, 3, 7, 165
 mortality risk, 7, 8
- CSF examination, 100
- cyclophosphamide, 114
- CYP2 gene, 71
- cytochrome P450, 71–72, 252
- cytomegalovirus, 79, 83
- deep brain stimulation (DBS), 63, 194,
 224
 ANT stimulation, 225–228
 mechanism of action, 228
- defined daily doses for ASMs, 22
- dentate gyrus, 87
- depomedroxyprogesterone, 193
- depression, 93, 146, 147, 176
 post resective surgery, 206
 postictal, 259
 post-surgery, 262
 prevalence, 257
 quality of life and, 261
- depth electrodes, 202, 203
- DESC syndrome, 111
- developing countries, 11
 botanical treatments, 248, 250
 course of epilepsy, 1
 Dianxianning tablets, 250, 252
- diet therapy. *See* low glycaemic index
 treatment, MCT diet, Modified
 Atkins Diet, ketogenic diet
- Dietary Supplement and Health
 Education Act (DSHEA), 251
- dietary supplements, 251
- digitalis, 248
- direct costs, 27–30, 32, 35
- discrimination, 34, 35
- DNET, 166
- dorsolateral region, 162
- double cortex syndrome, 81–82
- Dravet syndrome, 74, 75, 130–131, 150
 animal model, 55
 choice of treatment, 174
 genetics, 184
 SUDEP risk, 43
- driving, 35, 176
- drowning, 40
- DSM classifications, 257
- duty cycle, 220, 221
- dysmaturity hypothesis, 80
- early infantile epileptic
 encephalopathy (EIEE), 118–120
- early myoclonic epileptic
 encephalopathy (EMEE), 118–120
 case study, 120
- economics, 27–33, 35
 direct costs, 27–30, 32, 35
 employment-related costs, 35
 indirect costs, 27, 30–32
- EEG, 90
 discharges and cognitive
 impairment, 46
 interictal and ictal, 158, 163–165
 intracranial, 90, 163, 201, 202–205
 limitations of, 171
 scalp, 90
 stereo, 202
 video, 60, 172, 175, 198
- electrocorticographic (ECoG)
 monitoring, 231–234
- electrographic status epilepticus of
 sleep, 140–144
- elpetrigine, 182
- employment, 35, 206
 after surgery, 36
 quality of life and, 261
- encephalitis, 89, 166
 autoimmune, with seizures, 104–108
 limbic, 104
 paraneoplastic, 100
 Rasmussen's, 108
 viral, 88
- encephalomalacia, 200
- epilepsy. *See also* MRE
 5-year remission rates, 1, 2
 aetiology, 9, 10
 autoimmune. *See* autoimmune
 epilepsy
 causes of death, 8–10
 childhood-onset. *See* childhood-
 onset epilepsy
 developing countries, 1
 diagnosis limitations, 171
- economic impact, 27
 genetic variations, 70
 long-term outcome, 1
 misdiagnosis, 20
 mortality from, 7–11
 multifactorial basis of, 64, 65
 natural history of treated, 1–4
 natural history of untreated, 1
 psychiatric disorders and, 258
 remission rates, 15
 reproductive hormones and,
 187–190
- epilepsy centers, 60, 176, 265
- Epilepsy Foundation, 176
- Epilepsy Naturapedia, 253
- epilepsy with continuous spike wave of
 sleep (CSWS), 140–144, 150
- epilepsy with myoclonic absences,
 131–135, 150
- epileptic encephalopathies, 63
- epileptogenic zone, 198
- epileptogenicity, 63, 65, 66
 biomarkers of, 64
 hippocampal sclerosis, 89
- eslicarbazepine, 183
- estradiol, 187
- estrogen, 187, 188
- ethnobotany, 253
- ethosuximide, 51, 174
- euthyroid state, 110
- everolimus, 57, 174
- exosomes, 75
- eye closed sensitivity, 146
- eye closure sensitivity, 146
- eyelid myoclonia with and without
 absences, 146
- ezogabine, 120
- faciobrachial dystonic seizures, 104,
 106
- FDA regulations, 181
 botanical treatments, 251
- FDG-PET, 93, 104
- febrile convulsions, 88
- FEBSTAT study, 88
- fetus, effects of seizures on, 190
- FIRES syndrome, 111
- FLAIR imaging, 91, 104
- fluorofelbamate, 182
- focal cortical dysplasia (FCD), 79,
 80–82, 161
 ablative surgery, 213
 classification, 81
 models, 55
- focal epilepsy. *See also* mesial temporal
 lobe epilepsy
 AED treatment of, 183
 MRE diagnosis, 5
 resective surgery, 198
 treatment of, 63

- VNS, 220
 folic acid, 193
 forced normalization, 257, 260
 frontal lobe seizures, 162
 functional mapping, 204
 functional MRI (fMRI), 200
- GABA receptors, 54
 GABA-A receptor, 74, 182
 GABA-A receptor antibodies, 101, 107
 GABA-B receptor antibodies, 101, 107
 gabapentin, 51, 179, 183
 GABARG2 gene, 130
 GAD65 antibodies, 102, 108, 111, 115
 ganaxalone, 182
 gangliogliomas, 160, 166
 GEFS+, 56, 74, 130
 gelastic epilepsy, 167
 generalized tonic-clonic seizures (GTCS), 144
 models, 62
 mortality risk, 41
 SUDEP mechanism, 43, 44
 SUDEP risk factor, 42
 genes, epilepsy susceptibility, 74
 genetic biomarkers, 74
 genetics, 63, 69–76, 184
 ASM pharmacodynamics, 72
 ASM pharmacokinetics, 70–71
 Dravet syndrome, 130
 hippocampal sclerosis, 88
 inherited defects, 53
 MCD, 79
 non-pharmacological treatments and, 76
 pharmacogenetic online sources, 71
 genome-wide association studies (GWAS), 70
 gliosis, 200
 global treatment gap, 248
 GLUT1, 53, 174, 184
 GLUT1 deficiency, 242
 glycine receptor antibodies, 101, 107
 gonadotropin-releasing hormone (GnRH), 189
 GPR56 gene, 79
 grid electrodes, 202, 203
 GRIN2A gene, 142
- Hashimoto encephalopathy, 109–110
 hazard ratio, 46
 health-related quality of life (HRQOL), 36
 hemi-megalencephaly, 80–81
 heterotopia, 84–85
 hippocampal sclerosis, 53, 63, 87–97, 160
 acquired factors, 88
 bilateral, 90, 97, 99
 clinical features, 89–93
 etiology and pathogenesis, 87–89
 immune mechanisms, 89
 management, 94–95
 neuropsychology, 93
 other techniques, 95
 pathology, 95–97
 post-operative outcome, 95
 hippocampus, 87
 human capital model, 30
 human herpes virus 6, 161
 hypogonadotropic hypogonadism, 189
 hypospadias, 190
 hypothalamic hamartoma, 167–169
 ablative surgery, 212
 hypoxic ischaemic injury, 41, 79
 hysarrhythmia, 121–122
- ictal EEG, 158, 163–165
 ictal SPECT, 200
 ictogenicity, 63, 65, 66
 biomarkers of, 64
 idiopathic epilepsy, 3, 5, 7, 8
 IL-1 receptor antagonists (IL-1Ra), 115
 ILAE definition of MRE, 60, 4, 14, 20–26, 69, 180
 applications of, 25
 barriers to, 21
 need for, 20–24
 ILAE guidelines, 179
 hippocampal sclerosis, 87, 96
 immunoglobulin G (IgG), 112
 immuno-suppression, 114, 174
 immunotherapy, 104, 112
 response to, 101
 indirect costs, 27, 30–32
 infant syndromes, 121–135
 infantile spasm, 121–128, 149, 243
 MRI, 127
 infertility, 189, 193
 inflammation, 89
 inflammatory pathways, 184
 informed consent, 262
 inherited genetic defects, 53
 insulin, 63
 interictal dysphoric disorder, 260
 interictal EEG, 158, 163–165
 interictal psychiatric disorder, 256
 interictal psychosis, 257, 260
 interictal SPECT, 200
 International Bureau for Epilepsy, 176
 intracerebral tumors, 200
 intracranial EEG, 90, 163, 201, 202–205
 intravenous immunoglobulin (IVIg), 104, 105, 112
- Jeavons syndrome, 146–148, 151
 juvenile absence epilepsy, 144, 151
 juvenile myoclonic epilepsy, 135, 144–146, 151, 173, 174
- EEG, 144
 psychiatric disorders, 256
- KCNT1 gene, 56, 184
 ketogenic diet, 63, 53, 174, 241–246
 efficacy, 242
 implementation, 244
 indications and contraindications, 242–243
 mechanisms of action, 241
 side effects, 245
 Kuzniecky syndrome, 83, 84
- lacosamide, 183
 Lafora body disease, 135
 lamotrigine, 22, 54, 73, 179, 182, 183, 194
 Landau-Kleffner syndrome (LKS), 140–144, 150
 laser thermal ablation, 63
 lateral temporal lobe epilepsy, 158, 161
 lateralising signs, 90
 Lennox-Gastaut syndrome, 75, 120, 127, 133, 136–140, 150
 surgery, 148
 VNS, 220
 lesional epilepsy, resective surgery, 200, 201
 levetiracetam, 22, 51, 75, 147, 183
 lifestyle choices, 60
 lifestyle impact on MRE, 172–173
 limbic encephalitis, 104
 limbic seizures, 62
 lissencephaly, 81–82
 long QT (LQT) genes, 41, 45
 low glycaemic index treatment, 245
- magnet source imaging, 200
 magnetencephalography, 200
 magnetic resonance imaging (MRI)
 ablative surgery, 210, 213–216
 Dravet syndrome, 131
 epilepsy with myoclonic absences, 133
 fMRI, 200
 hippocampal sclerosis, 90–92, 94
 infantile spasm, 127
 lesions, 6
 limitations of, 171
 seizure onset zone, 198, 200
 magnetic resonance proton spectroscopy, 92
 major congenital malformations (MCMs), 190, 191, 193
 malformation of cortical development (MCD), 79–85, 165, 200
 aetiology of, 79
 clinical classification, 80–85
 epilepsy mechanism, 80
 hippocampal sclerosis and, 97

Index

- malignant migrating partial seizures of infancy, 56
 maximal electro-shock (MES), 54, 62
 MCT diet, 245
 medication-resistant epilepsy. *See* MRE
 megalencephaly, 80–81
 memory impairment, 47, 93, 95, 176
 memory outcome, post resective surgery, 206
 meningitis, 88
 menstrual cycle, 188, 192
 mesial temporal lobe epilepsy, 63, 158, 161, 176
 ablative surgery, 213, 215
 hippocampal sclerosis, 160
 interictal and ictal EEG, 158
 response to treatment, 161
 seizure semiology, 158
 mesial temporal sclerosis, 112, 200
 metabotropic glutamate receptor 5 (mGluR5) antibodies, 107
 methylprednisolone, 112
 microRNAs (miRNAs), 17
 migrating partial epilepsy of infancy, 128–130, 150
 models for MRE, 51–58, 62
 animal. *See* animal models
 findings in humans, 52–53
 historic perspective, 51–52
 known mechanisms, 56–58
 scope of the problem, 52
 Modified Atkins Diet, 244
 monoclonal antibodies, 114
 monotherapy following treatment failure, 180–181
 Monteris anchoring device, 211
 mood disorders, 176
 morbidity, 39, 46–47
 cognitive, 46
 costs of MRE, 31
 mortality, 7–11, 39–41, *See also* SUDEP
 causes of, 8–10, 40
 costs of MRE, 31
 Dravet syndrome, 131
 risk, 40–41
 MORTEMUS study, 43
 motor evoked potential (MEP) amplitude, 236
 MRE, 20–21, *See also* anti-seizure medications (ASMs), epilepsy
 additional care elements, 176
 alternative pharmacotherapies, 184–185
 challenges in identifying, 14–18
 diagnosis, accuracy, 171–172
 diagnosis, differential, 60–61
 diagnosis, timing of, 5–6
 economic impact, 27–33
 epidemiology, 4
 features associated with, 24
 ILAE definition of. *See* ILAE
 definition of MRE
 lifestyle impact on, 172–173
 models for. *See* models for MRE
 mortality in, 10–11
 neurobiology. *See* neurobiology of MRE
 predictive factors for, 6–7, 16–17
 prevalence, 20
 psychiatric comorbidities. *See* psychiatric comorbidities
 seizure burden goals, 175–176
 social consequences, 34–37
 trajectory of, 7
 transport problems in, 52, 53
 treatment of, 64, 174–175
 treatment, additional goals, 176
 types of, 62–66
 women with, 187
 multi-drug resistance (MDR), 64, 72
 mycophenolate mofetil, 114
 myoclonic astatic epilepsy, 140, 150
 myoclonic epilepsy
 early, 118–120
 juvenile. *See* juvenile myoclonic epilepsy
 progressive, 135, 150, 184
 myoclonus, 144
 N-acetylaspartate, 92
 National Association of Epilepsy Centers, 265
 neocortical epilepsies, 161–167
 interictal and ictal EEG patterns, 163–165
 pathomorphologies, 165–166
 resective surgery, 206
 response to treatment, 167
 seizure semiology, 161–164
 neonatal syndromes, 118–121
 neurobiology of MRE, 67
 at outset, 63
 biomarkers, 64–66
 progressive development, 63–64
 types of MRE, 62–66
 NeuroBlast system, 210
 neurocysticercosis, 61, 161
 neurologic disorders, 46
 neuronal cell surface antibody syndromes, 104–107
 neuronal ceroid lipofuscinoses, 135
 neuronal intracellular antibody syndromes, 108
 neuropsychological testing, 200
 neurosarcoidosis, 110
 neurosteroids, 57
 neurostimulation, 194
 responsive. *See* responsive neurostimulation
 trigeminal, 63, 222
 NICE guidelines, 179, 180
 NMDAR, 187
 NMDAR encephalitis, 100, 101, 106–107, 112
 nocturnal seizures, SUDEP and, 43
 nonadherence, 60, 172
 non-epileptic seizures, 60, 172
 non-lesional epilepsy, resective surgery, 200, 202–203
 non-paraneoplastic encephalitis, 100
 NORSE syndrome, 111
 obstetric risks, 191
 Ohtahara syndrome, 118–120
 oligodendrogliomas, 160
 onconeural antibodies, 108, 112, 115
 operculum, 162
 orbitofrontal region, 162
 oxcarbazepine, 183
 padsevonil, 182
 Papez circuit, 224
 paraneoplastic antibodies, 108
 paraneoplastic encephalitis, 100
 parieto-occipital lobe seizures, 162
 PCDH19-FE epilepsy, 57
 pentylentetrazol (PTZ), 51, 54, 62
 peri-ictal psychiatric disorder, 256, 257
 perisylvian cortex, 83
 periventricular nodular heterotopia, 84
 Perry-Romberg syndrome, 110
 personality disorders, 257
 P-glycoprotein (Pgp), 52, 53, 64, 72
 pharmacodynamics, ASMs, 69, 72, 265
 pharmacogenetics online sources, 71
 pharmacokinetics, 179
 ASMs, 69, 70–71
 PharmGKB website, 71, 73
 phenobarbital, 2, 51, 190
 phenytoin, 51, 54, 71, 73
 phytocannabinoids, 75
 placebo-controlled trials, 181, 182
 plasma exchange, 104, 114
 pneumonia, 9
 polycystic ovary syndrome, 189, 193
 polymicrogyria, 80, 83–84
 polytherapy
 following treatment failure, 180–181
 pregnancy and, 190
 rational, 173, 181
 positron emission tomography (PET), 93, 104
 postencephalitic lesions, 166
 postictal depression, 259
 postictal generalized EEG suppression (PGES), 43, 44

- postictal psychiatric phenomena, 256, 259
- postictal psychosis, 257, 259
- precipitating factors, 65
- pregabalin, 183
- pregnancy, 190–192
 - adverse effects of ASMs, 190–191
 - adverse effects of seizures, 190
 - management during, 193
 - management post-delivery, 194
 - management pre-pregnancy, 193
 - seizure risk during, 190
 - serum levels of ASMs, 191
- primary motor cortex, 162
- progesterone, 187, 188, 192
- progressive myoclonic epilepsy, 135, 150, 184
- propionate mortality ratio (PMR), 8
- pseudo-MRE, 60–61, 20
- psychiatric comorbidities, 9, 17, 256–266. *See also* depression
- epidemiology, 257–258
- epilepsy and, 258
- hippocampal sclerosis, 93
- impact on patient's life, 261–264
- obstacles to treatment, 265
- treatment of, 264–265
- psychiatric disorders, DSM
 - classifications, 257
- psychogenic non-epileptic seizures, 60, 172
- psychological outcome, post-operative, 95
- psychosis, 257
 - alternative, 257, 260
 - interictal, 257, 260
 - postictal, 257, 259
- psychotropic drugs, 264–265
- PWE (people with epilepsy). *See* MRE, epilepsy
- pyruvate dehydrogenase deficiency, 243
- QOLIE-89 inventory, 261
- quality of life, 34, 35
 - after surgery, 36
 - measures, 176
 - post resective surgery, 206
 - psychiatric comorbidities and, 261
- quinidine, 130, 184
- radiosurgery or open surgery (ROSE), 95
- randomized controlled trials (RCTs), 179, 181–182
- rapamycin, 57
- Rasmussen's encephalitis, 108
- rational polytherapy, 173, 181
- reactive seizures, 61
- regulatory trials, shortcomings of, 181–182
- renal calculi, 245
- reproductive hormones, 187–190
- resective surgery, 198–207. *See also* surgery
 - functional mapping, 204
 - procedures and outcome, 204–206
 - seizure onset zone, 198–201
 - surgical margins, 201–203
 - tradeoffs, 206
- respiratory dysfunction, 44, 45
- responsive neurostimulation, 63, 95, 194, 230–234
- retigabine, 120
- risk activities, 176
- rituximab, 114
- safety
 - botanical treatments, 251
 - risk activities, 176
 - TMS, 238
- safinamide, 182
- SANAD trial, 179, 180
- SANTE trial, 226–228
- scalp EEG, 90
- schizophrenia, 257
- schizophrenia-like psychosis of epilepsy (SLPE), 257, 261
- SCN1A gene, 73, 74, 130, 131, 184
- SCN1B gene, 130
- SCN2A gene, 73
- SCN3A gene, 73
- seizure burden goals, 175–176
- seizure freedom, 36, 175
 - post-operative, 95
 - rates of, 16
- seizure frequency, 46, 181
- seizure onset zone, 198–201
- seizure semiology, 89–90
 - mesial temporal lobe epilepsy, 158
 - neocortical epilepsies, 161–164
- seizure threshold, 65
- selective amygdalohippocampectomy, 94
- seronegative autoimmune limbic encephalitis (SNALE), 111
- serum levels of ASMs, 191
- sialidosis, 135
- single-photon emission computed tomography (SPECT), 93, 200
- SISCOM, 200
- sleep deprivation, 173
- small for gestational age, 190
- social consequences, 34–37
- social support, 176
- sodium valproate. *See* valproate
- Spencer type resection, 94
- spina bifida, 190
- SREAT, 109
- standardized mortality ratio (SMR), 39, 40
- status epilepticus
 - costs involved, 36
 - electrographic, of sleep, 140–144
 - hippocampal sclerosis and, 88
 - mortality, 40
 - TMS, 238
- stereo-EEG, 202
- stereotactic laser ablation (SLA). *See* ablative surgery
- stigma, 34, 35
- stiripentol, 131
- stress, 173
- strip electrodes, 202, 203
- stroke, 166
- substance abuse, 61, 9
- SUDC (sudden unexplained death in childhood), 41
- SUDEP, 8, 10, 40, 41–45
 - age distribution, 41
 - definition, 41–42
 - genetic markers, 43
 - incidence, 41
 - mechanisms, 43–45
 - neuropathology, 45
 - post resective surgery, 206
 - prevention, 45
 - risk factors, 42–44
- suicide, 40, 263
- sulfamethoxazole, 112
- supplementary motor area, 162
- suppression burst pattern, 118, 120
- surgery, 63. *See also* ablative surgery, resective surgery
 - ANT stimulation, 228
 - autoimmune epilepsy, 114
 - childhood epilepsy, 148
 - hippocampal sclerosis, 94–95
 - psychiatric comorbidity effect on, 262–263
 - quality of life after, 36
 - women with epilepsy, 194
- surgical margins, 201–203
- symptomatic epilepsy, 7, 8, 10
 - mortality risk, 7
 - MRE predictor, 16
- symptomatogenic zone, 198, 199
- synaptic plasticity, 53
- systemic autoimmune disorders, 109–110
- systemic lupus erythematosus, 109
- T2000, 182
- target hypothesis, 52
- temporal lobe epilepsy
 - lateral, 158, 161
 - memory difficulties, 47
 - mesial. *See* mesial temporal lobe epilepsy

Index

- temporal lobe epilepsy (cont.)
 models of, 52
 resective surgery, 205
 tetrahydrocannabinol, 253
 tiagabine, 183
 tocilizumab, 114
 tonabersat, 182
 tonic seizures, 136
 topiramate, 179, 183, 190
 toxoplasmosis, 79
 Traditional Chinese Medicine (TCM),
 248, 249, 250, 252
 transcranial magnetic stimulation
 (TMS), 236–239
 clinical trials, 236–238
 mechanism of action, 236
 safety and side effects, 238
 status epilepticus, 238
 transcutaneous VNS, 221
 transition of care in epilepsy,
 149
 transport problems in MRE, 52, 53
 transporter hypothesis, 52
 traumatic brain injury, 164, 166
 trigeminal neurostimulation (TNS),
 63, 222
 trimethoprim, 112
 TSC1/2 genes, 56, 63
 tuberous sclerosis, 56, 63, 174
 ablative surgery, 213
 tubulinopathies, 81–82
 tumors
 autoimmune epilepsy, 108, 112, 115
 brain, 165
 intracerebral, 200
 mesial temporal lobe epilepsy, 160
 Unverricht–Lundborg disease, 135
 US Equal Employment Opportunity
 Commission (EEOC), 35
 vagus nerve, 219
 vagus nerve stimulation (VNS), 63, 194
 adverse effects, 222
 efficacy, 219
 mechanism of action, 219
 patient selection, 220
 practical considerations, 220
 programming, 221–222
 stimulation parameters, 221
 valproate, 73, 174, 179
 adverse effects, 179
 reproductive hormones and, 189
 risk during pregnancy, 190
 valroceamide, 183
 vascular malformations, 165, 200
 VGKC complex antibodies, 101,
 104–106
 video-EEG, 60, 172, 175, 198
 vigabatrin, 114, 183
 viral encephalitis, 88
 visual field defects, 94
 Visualase system, 210, 212
 water diet, 241
 West syndrome, 120, 121, 128
 WHO, defined daily doses of ASMs, 22
 Wyler score, 96
 zebrafish models, 55, 56
 Zhenxian pills, 250
 zonisamide, 183